Iboga and ibogaine is attracting serious scientific attention across a range of conditions where conventional medicine has reached its limits; Parkinson’s disease, treatment-resistant depression, PTSD, and traumatic brain injury among them. This session presents what current research is showing, what remains unknown, and what rigorous, ethical investigation should look like. Who leads that process, and on whose terms?